|Conditional recommendation based on very-low-quality evidence; may consider switching to a different TNFi biologic monotherapy if the patient has demonstrated MTX-associated adverse events, prefers to receive fewer medications, or perceives MTX as a burden.|Conditional recommendation based on very-low-quality evidence; may consider switching to a different TNFi biologic monotherapy if the patient has demonstrated MTX-associated adverse events, prefers to receive fewer medications, or perceives